Line of Credit 
Print FormatAlmost 400M COVID-19 Vaccine Doses Lost Due To Emergent's Baltimore Plant Fiasco
- According to a recent report from the US House select subcommittee on the coronavirus crisis, Emergent Biosolutions Inc NYSE:EBS might have destroyed nearly 400 million doses of COVID-19 vaccines after failing to meet quality standards.
- Initially, 75 million - 85 million doses of drug substance were said to be destroyed after contamination.
- "Despite major red flags at its vaccine manufacturing facility, Emergent's executives swept these problems under the rug and continued to rake in taxpayer dollars," Rep.
Carolyn Maloney said. - Emergent hid the evidence, the report alleges, by removing quality-assurance hold tags from Johnson & Johnson NYSE: JNJ COVID-19 shot batches that indicated that the containers had quality issues.
- Related: Millions Of JNJ COVID-19 Shots Sit Idle At Emergent's Baltimore Plant: Reuters.
- The report also says that Emergent entered contracts with the two companies despite knowing that technical operations were not up to snuff for at least a few years.
- The CDMO maintains that it never knowingly misled the FDA or any partners involved in the manufacturing process.
- The report says that President
Donald Trump 's administration was aware of deficiencies highlighted at the Bayview site when it received$628 million in funding inMay 2020. - AstraZeneca Plc NASDAQ:AZN personnel raised concerns to Emergent in July of 2020.
- The report also found that inexperienced staff and the high turnover led to vaccine contamination.
- Price Action: EBS shares are down 8.03% at
$27.96 on Wednesday. - Image by torstensimon from Pixabay
